Literature DB >> 2160882

Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.

V J Dzau1.   

Abstract

The contribution of plasma versus tissue angiotensin-converting enzyme (ACE) to pathophysiology and drug effect is reviewed. The data suggest that tissue ACE is important in influencing local angiotensin levels and that the long term response to an ACE inhibitor is dependent on its action on tissue ACE. The tissue penetration and distribution of various ACE inhibitors may determine their duration of action and the relative effects on different organs, thereby influencing regional blood flow and tissue function. This concept of tissue ACE has improved our understanding of the mechanisms of action of ACE inhibition in the treatment of hypertension and heart failure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160882     DOI: 10.2165/00003495-199000392-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  36 in total

Review 1.  Significance of the vascular renin-angiotensin pathway.

Authors:  V J Dzau
Journal:  Hypertension       Date:  1986-07       Impact factor: 10.190

2.  Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.

Authors:  W H van Gilst; P A de Graeff; H Wesseling; C D de Langen
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

3.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group.

Authors: 
Journal:  JAMA       Date:  1988 Jan 22-29       Impact factor: 56.272

4.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

5.  Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.

Authors:  N Sharpe; J Murphy; H Smith; S Hannan
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

6.  Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril.

Authors:  O A Carretero; S Miyazaki; A G Scicli
Journal:  Hypertension       Date:  1981 Jan-Feb       Impact factor: 10.190

7.  Angiotensin I, II, and III in sheep. A model of angiotensin production and metabolism.

Authors:  D T Fei; B A Scoggins; G W Tregear; J P Coghlan
Journal:  Hypertension       Date:  1981 Nov-Dec       Impact factor: 10.190

Review 8.  Implications of local angiotensin production in cardiovascular physiology and pharmacology.

Authors:  V J Dzau
Journal:  Am J Cardiol       Date:  1987-01-23       Impact factor: 2.778

9.  Captopril-induced changes in large arteries in essential hypertension.

Authors:  A C Simon; J A Levenson; J L Bouthier; M E Safar
Journal:  Am J Med       Date:  1984-05-31       Impact factor: 4.965

10.  Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts.

Authors:  W Linz; B A Schölkens; Y F Han
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more
  7 in total

Review 1.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Disposition of quinapril and quinaprilat in the isolated perfused rat kidney.

Authors:  A R Kugler; S C Olson; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1995-06

Review 3.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

4.  Mechanical strain and collagen potentiate mitogenic activity of angiotensin II in rat vascular smooth muscle cells.

Authors:  K Sudhir; E Wilson; K Chatterjee; H E Ives
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

Review 5.  ACE-I/ARB therapy prior to contrast exposure: what should the clinician do?

Authors:  Robert Kalyesubula; Peace Bagasha; Mark A Perazella
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

6.  Association of angiotensin-converting enzyme G2350A gene polymorphisms with hypertension among patients with intracerebral haemorrhage.

Authors:  Imran Imran; Syahrul Syahrul; Sofia Sofia; Farida Farida; Nasrul Musadir; Jonny K Fajar
Journal:  J Taibah Univ Med Sci       Date:  2019-05-25

Review 7.  Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity.

Authors:  Muhammad Manjurul Karim; Shahnaz Sultana; Rokaia Sultana; Mohammad Tariqur Rahman
Journal:  J Infect Public Health       Date:  2021-10-04       Impact factor: 3.718

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.